Paper · 2016 · Open access

Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.

Alan L. Shields, Yanni Hao, Meaghan Krohe, Andrew Yaworsky, Iyar Mazar, Catherine Foley, Faisal Mehmed, DENISE R. GLOBE

Europe PMC (PubMed Central), 9(4), 188–197 · Published 1 June 2016

Open full textCite this paper

In brief

“Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.” is a 2016 paper by Alan L. Shields and 7 co-authors, published in Europe PMC (PubMed Central). OpenAlex counts 14 citations as of 22 November 2026. It is open access: the full text is free to read at Europe PMC (PubMed Central).

Citations
14
Most cited in
2022 (4)
Field-weighted impact
1.70
References
37
Authors
8

Abstract

BACKGROUND: Despite an increased use of patient-reported outcomes (PROs) in oncology clinical trials, integrating the patient perspective into drug approval decisions and documentation has been challenging. OBJECTIVES: To review important regulatory and measurement terminology, and to provide oncology outcomes researchers and those involved with building oncology programs with tools to plan PRO data collection, particularly in relation to drug efficacy claims for drug labeling in the United States. DISCUSSION: When contemplating a PRO measurement strategy for oncology clinical trials, outcomes researchers are challenged in several ways. First, given multiple stakeholders, researchers must communicate with their scientific, commercial, and regulatory colleagues using often misunderstood terms, such as "label," "claim," "end point," "outcome," and "concept." Second, because stakeholders do not always have access to data from early-stage clinical trials and do not contribute to the target drug's profile in early development, researchers are often unable to address the most important question in building a measurement strategy: What do we want to say about our drug? To overcome these challenges, researchers can systematically develop an end point model to facilitate communication among drug development stakeholders using a common language and to link the building blocks of a PRO measurement strategy, including claims, concepts, questionnaires, and end points. We developed a model that characterizes a disease by its proximal signs and/or symptoms and increasingly distal health outcomes to provide researchers potential measurement concepts that can be instrumental in selecting PRO questionnaires for use in studies. CONCLUSION: PRO data collected in clinical trials should be used in drug development to evaluate the drug's efficacy; it is encouraging that US regulators are willing to work with drug sponsors to overcome the challenges associated with the development, implementation, and interpretation of PROs. The tools discussed in this article can facilitate the planning process for oncology researchers, as well as assist in communicating with US regulators.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Shields, A. L., Hao, Y., Krohe, M., Yaworsky, A., Mazar, I., Foley, C., Mehmed, F., & GLOBE, D. R. (2016). Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges. Europe PMC (PubMed Central), 9(4), 188–197. https://www.ncbi.nlm.nih.gov/pmc/articles/5004817

MLA 9

Shields, Alan L., et al. “Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.” Europe PMC (PubMed Central), vol. 9, no. 4, 2016, pp. 188–197. https://www.ncbi.nlm.nih.gov/pmc/articles/5004817.

Chicago

Shields, Alan L., Yanni Hao, Meaghan Krohe, Andrew Yaworsky, Iyar Mazar, Catherine Foley, Faisal Mehmed, and DENISE R. GLOBE. 2016. “Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.” Europe PMC (PubMed Central) 9 (4): 188–197. https://www.ncbi.nlm.nih.gov/pmc/articles/5004817.

Harvard

Shields, A. L. et al. (2016) ‘Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.’, Europe PMC (PubMed Central), 9(4), pp. 188–197. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/5004817.

IEEE

A. L. Shields et al., “Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.,” Europe PMC (PubMed Central), vol. 9, no. 4, pp. 188–197, 2016.

BibTeX

@article{shields2016patient,
  title     = {{Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.}},
  author    = {Shields, Alan L. and Hao, Yanni and Krohe, Meaghan and Yaworsky, Andrew and Mazar, Iyar and Foley, Catherine and Mehmed, Faisal and GLOBE, DENISE R.},
  journal   = {Europe PMC (PubMed Central)},
  year      = {2016},
  volume    = {9},
  number    = {4},
  pages     = {188--197},
  url       = {https://www.ncbi.nlm.nih.gov/pmc/articles/5004817}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201711
201811
201922
202011
202244
202411
202511
202633

Its field-weighted citation impact is 1.70: it has been cited 1.70 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • patient-reported outcomes
  • drug approval
  • regulatory communication
  • measurement concepts
  • early-stage clinical trials
  • drug development

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Shields, A. L., Hao, Y., Krohe, M., Yaworsky, A., Mazar, I., Foley, C., Mehmed, F., & GLOBE, D. R. (2016). Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges. Europe PMC (PubMed Central), 9(4), 188–197. https://www.ncbi.nlm.nih.gov/pmc/articles/5004817

How many times has this paper been cited?

14 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Europe PMC (PubMed Central): sign in and open the full text from this page.

Who wrote this paper?

Alan L. Shields, Yanni Hao, Meaghan Krohe, Andrew Yaworsky, Iyar Mazar, Catherine Foley, Faisal Mehmed, DENISE R. GLOBE.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.